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Abstract
Background and Aims: The small intestine is the major site of absorption of dietary sugars. The rate at which they enter and
exit the intestine has a major effect on blood glucose homeostasis. In this study, we determine the effects of luminal leptin
on activity/expression of GLUT2 and GLUT5 transporters in response to sugars intake and analyse their physiological
consequences.
Methodology: Wistar rats, wild type and AMPKa2
2/2 mice were used. In vitro and in vivo isolated jejunal loops were used to
quantify transport of fructose and galactose in the absence and the presence of leptin. The effects of fructose and galactose
on gastric leptin release were determined. The effects of leptin given orally without or with fructose were determined on
the expression of GLUT2/5, on some gluconeogenesis and lipogenic enzymes in the intestine and the liver.
Principal Findings: First, in vitro luminal leptin activating its receptors coupled to PKCbII and AMPKa, increased insertion of
GLUT2/5 into the brush-border membrane leading to enhanced galactose and fructose transport. Second in vivo, oral
fructose but not galactose induced in mice a rapid and potent release of gastric leptin in gastric juice without significant
changes in plasma leptin levels. Moreover, leptin given orally at a dose reproducing comparable levels to those induced by
fructose, stimulated GLUT5-fructose transport, and potentiated fructose-induced: i) increase in blood glucose and mRNA
levels of key gluconeogenesis enzymes; ii) increase in blood triglycerides and reduction of mRNA levels of intestinal and
hepatic Fasting-induced adipocyte factor (Fiaf) and iii) increase in SREBP-1c, ACC-1, FAS mRNA levels and
dephosphorylation/activation of ACC-1 in liver.
Conclusion/Significance: These data identify for the first time a positive regulatory control loop between gut leptin and
fructose in which fructose triggers release of gastric leptin which, in turn, up-regulates GLUT5 and concurrently modulates
metabolic functions in the liver. This loop appears to be a new mechanism (possibly pathogenic) by which fructose
consumption rapidly becomes highly lipogenic and deleterious.
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Introduction
The small intestine is involved in delivering sugars to the
systemic circulation through absorption of the products arising
from carbohydrate digestion. The rate at which dietary sugars
enter and exit the intestinal epithelium has a major effect on blood
glucose concentration and homeostasis. Briefly, dietary carbohy-
drates are taken into the enterocytes by specific transporters and
exit the cell through the basolateral GLUT2 transporter [1,2]. In
pre-prandial state, glucose transport is an active process which
involves the co-transport of sugar with sodium ions through the
sodium-glucose transporter-1, SGLT-1. In prandial state, when
higher concentrations of glucose or galactose are found in the
intestinal lumen, apical GLUT2 becomes active providing the
small intestine with an absorptive capacity to match dietary intake
during meal [1]. This apical GLUT2 transporter also participates
to fructose transport in addition to the main and specific GLUT5
transporter [3]. All these membrane transporters are highly
regulated during food intake by changing their activity levels, their
location within the enterocyte and by regulating the expression of
the encoding genes [4]. They are also controlled by b-adrenergic
agonists [5], gastrointestinal hormones such as glucagon-like
peptide-2, GLP-2 [6,7], glucose-dependent insulinotropic poly-
peptide, GIP, cholecystokinin (CCK) [8], and by leptin [9].
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7935Initially characterized as an adipocyte specific protein control-
ling body weight and adiposity, leptin is now considered as an
hormone with pleiotropic biological effects. This status of leptin is
consistent with the production of leptin by various tissues and
organs including the stomach. The stomach-derived leptin is
rapidly and mainly secreted into the gastric juice after a meal [10]
where it is not fully degraded even at pH 2 [10,11]. The released
leptin enters the intestine and is detected in intestinal juices from
duodenum to the colon as both free leptin and leptin bound to its
soluble receptor Ob-Re [12,13] as previously reported for plasma
leptin. The demonstration that leptin receptors are present all
along the small and large intestine [14,15], are in line with leptin,
acting at the luminal side to enhance intestinal absorption of
oligopeptides mediated by the proton-dependent PepT1 trans-
porter [14], to increase monocarboxylate transporter MCT-1
butyrate uptake in Caco-2 cells [16], and to inhibit the active
component of glucose absorption mediated by SGLT-1 [9].
However, whether the apical GLUT2 transporter [1] which is
active during a meal and the fructose GLUT5 transporter can be
direct targets for luminal leptin, is unknown.
The aim of the present study was to investigate the effects of
luminal leptin (mimicking gastric leptin) on the transport activities
and expression of GLUT2 and GLUT5 transporters in the small
intestine and to analyse the intracellular mechanisms involved.
Since fructose represents an important ingredient in human diets
due to the extensive use of high-fructose sweeteners [17,18], and it
has been described as a contributing factor in the metabolic
syndrome, we analysed the in vivo effects of luminal leptin
regulation of fructose absorption on some key indices of lipid
and carbohydrates metabolism. Then, we questioned the physi-
ological relevance of the data by determining whether fructose
ingestion modulated gastric leptin and whether this leptin is
actually entering into the intestinal lumen.
In this study, we demonstrated that luminal leptin, acting from
lumen of the intestinal epithelium, increases GLUT2 and GLUT5
transport activities through leptin-receptor coupled to activation of
protein kinase C subunit bII (PKCbII) and 59AMP-activated
protein kinase subunit a (AMPKa). We also demonstrated, for the
first time, that oral fructose rapidly induces the release of leptin in
the gastrointestinal lumen without significantly affecting plasma
leptin levels. Moreover, in vivo oral leptin-induced stimulation of
GLUT5-mediated fructose transport has several consequences: i) a
significant rise in blood glucose levels associated with changes in
mRNA levels of key gluconeogenesis enzymes; ii) an increase in
circulating levels of triglycerides associated with a reduced
transcription of intestinal and hepatic fasting-induced adipocyte
factor (Fiaf), encoding a secreted lipoprotein lipase (LPL) inhibitor,
and iii) enhanced transcription of sterol regulatory element-
binding protein-1c (SREBP-1c), acetyl-coA carboxylase isoform 1
(ACC-1) and fatty acid synthase (FAS) in the liver.
Results
Luminal Leptin Increases GLUT5-Mediated Fructose
Transport
Addition of leptin into jejunum loop in vitro, induced a
concentration-dependent increase in Papp of [
14C]-fructose (fig. 1,
A) with a maximal increase occurring with 1 nM leptin (P,0.01
vs. CTRL). This transepithelial transport of fructose was rapid and
time-dependently increased with 1 nM leptin added into the
jejunum (fig. 1, B). Addition of CCK-8 in the serosal side did not
significantly affect fructose transport. Under these conditions,
luminal addition of leptin had no effect on [
14C]-mannitol
transport (data not shown), indicating that the increase in fructose
Figure 1. Luminal leptin increases GLUT2 and GLUT5 transport
activities. Dose-response effect for luminal leptin stimulation of
mucosal (M) to serosal (S) fructose [30 mM, (1, A)] or galactose
[100 mM, (1, E)] transepithelial transport in the isolated rat jejunal
loops in vitro. CCK8 (8 pM) was added to the serosal side. Data are
expressed as apparent permeability (Papp) and each column represents
the mean6SEM of n=6 rats. B, F, Kinetic of luminal leptin stimulation
of fructose (B) or galactose (F) transport in the isolated rat jejunal loops
in vitro. CCK8 (8 pM) was added in the incubation medium (serosal side).
C, G, Effects of phloretin (PHLO, 1 mM) and cytochalasin B (CytoB,
20 mM), two GLUT2 inhibitors, on basal and leptin-induced mucosal to
basolateral fructose (C) and galactose (G) transport in the isolated rat
jejunal loops in vitro. Data are expressed as apparent permeability
(Papp) and each column represents the mean6SEM of n=8 rats. D, H,
Representative immunoblots of GLUT5, GLUT2 and b-actin proteins in
brush-border membranes from rat jejunum treated with or without
luminal leptin in association with or without fructose (30 mM) and
galactose (100 mM) into the isolated jejunal loop. Results of
densitometric analysis are expressed as relative protein levels.
*P,0.05; **P,0.01,*** P,0.001 vs. NaCl.
doi:10.1371/journal.pone.0007935.g001
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tissue permeability.
On the other hand, addition of phloretin significantly reduced
by 20% (P,0.05) both basal- and leptin-stimulated fructose
transport (fig. 1, C) consistent with the involvement of a small
component of GLUT2 in fructose transport [3]. The addition of
cytochalasin B also reduced basal and suppressed leptin-stimulated
fructose transport (fig. 1, C).
The intestinal absorption of sugars is often associated with
substrate-induced translocation of transporters to apical mem-
branes [1,19]. We observed that leptin-stimulated fructose
transport was associated with an increased level of GLUT5
protein in the BBM (fig. 1, D). Thus, luminal fructose induced a
2.2-fold increase in the levels of GLUT5 in the BBM (P,0.01 vs.
CTRL) and when combined with leptin, this level was 3.4 times
higher than in controls.
Luminal Leptin Increases GLUT2-Mediated Galactose
Transport
As for fructose transport, addition of leptin into rat jejunum
loop in vitro induced a concentration-dependent increase in
galactose uptake (fig. 1, E). The maximal effect of leptin on
apparent permeability (Papp) of galactose (2-fold increase; P,0.01
vs. control) occurred with 5 nM luminal leptin compared to 1 nM
for fructose transport. These apparent different sensitivities of
GLUT2 and GLUT5 could be related to the high concentration of
galactose used in the study taking into account the differences in
Km of the two transporters and, we used the dose of 5 nM for the
time course studies for galactose transport. In fig. 1F, [
14C]-
galactose transport across the jejunum (mucosal to serosal)
significantly increased over time; this effect was enhanced by
luminal addition of 5 nM leptin. Addition of CCK-8 at the serosal
side (incubation bath) had no significant effect. Moreover, the
leptin stimulation of galactose transport was markedly reduced by
phloretin and cytochalasin B, two inhibitors of GLUT2 trans-
porter (fig. 1, G) suggesting that GLUT2 transporter is a direct
target of leptin. In fig. 1H, we found that luminal leptin
significantly increased the levels of GLUT2 at the BBM: with
1 nM leptin, GLUT2 levels increased by 2-fold (P,0.01 vs.
control). Galactose (100 mM) induced a 3-fold increase in GLUT2
levels in the BBM and this effect was not further increased by
addition of leptin into the jejunum.
Leptin’s Action Is Leptin-Receptor Specific
To address receptor specificity of leptin’effects, we used the
murine L39A/D40A/F41A leptin mutein, a recent developed
recombinant leptin analog in which alanine was substituted for
amino acids expressed in positions 39, 40, and 41 of wild-type
leptin. This leptin mutein behaves as an antagonist of leptin
receptor [20,21]. In fig. 2, we found that addition of L39A/D40A/
F41A mutein into isolated jejunal loops in vitro did not affect basal
[
14C]-galactose (fig. 2, A) or [
14C]-fructose (fig. 2, B) transport but
Figure 2. Actions of leptin require active jejunal leptin receptors. Effects of a leptin receptor antagonist, L39A/D40A/F41A mutein on basal
and luminal leptin-stimulated mucosal to serosal D-galactose (A) and D-fructose (B) transport across the rat jejunum. Shown are apparent
permeability (Papp) of galactose and fructose across the jejunum. Each column represents mean6SEM for n=6 rats. Statistical analysis was
performed using One-way ANOVA followed by a Tukey Kramer multiple comparisons *P,0.05, ***P,0.001 vs. control. (C) Leptin receptors in the
jejunum mucosa are functional. Shown are representative immunoblots (4 separate experiments) of phosphorylated ERK-1/2 and total ERK proteins
in extracts from isolated jejunum treated with luminal leptin or fructose or both in association. The introduction of leptin into jejunum increased
phosphorylation of ERK-1/2. Luminal fructose also increased phosphorylation of ERK-1/2, an effect that was further enhanced by leptin. AICAR, the
pharmacological activator of AMPK increased the phosphorylation ERK-1/2.
doi:10.1371/journal.pone.0007935.g002
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and fructose transport.
In addition, in rat, the in vivo leptin stimulation of GLUT2-
mediated galactose transport was associated with a rise of galactose
levels in the blood (Text S1, fig. S1). Moreover, addition of L39A/
D40A/F41A, a leptin antagonist, completely prevented leptin-
induced increase in blood galactose (fig. S1). This indicates that the
effects of luminal leptin are dependent upon leptin receptor,
consistent with our previous data using leptin-receptor deficient
fa/fa rats [12,9].
These leptin receptors were further demonstrated to be
functional since they are responsive to luminal leptin alone or
combined with luminal fructose (fig. 2, C). Indeed, activation of
leptin receptor by introduction of leptin into the lumen of the
jejunum loop, increased phosphorylation of ERK-1/2 consistent
with the well-known coupling of activated leptin-receptor to
MAPkinase signaling pathways. It is noteworthy that luminal
fructose increased phosphorylation of ERK-1/2, an effect that was
further enhanced by leptin. Similarly, AICAR, a pharmacological
activator of AMPK, induced a strong phosphorylation of ERK-1/
2 proteins in jejunal mucosa. These data can be compared with
the capacity of central fructose to sense via activation of
hypothalamic AMPK/malonyl-CoA signaling pathways [22].
The Leptin Stimulation of Fructose Transport Is
Associated with Increase Phosphorylated PKCbII in the
BBM
Previous studies have shown that the increase in recruitment of
sugar transporters to the BBM requires activation of the bII-
isoenzyme of protein kinase C [23]. In this study, luminal fructose
increased phosphorylation of PKCbII in the BBM, an effect which
was further enhanced by addition of 1 nM leptin into the jejunum
(fig. 3, A). These data might indicate that leptin enhances fructose
transport, by increasing phosphorylation/activation of PKCbII
and by recruiting more GLUT5 proteins into the BBM.
Leptin-Stimulated Fructose Transport Results in a
Concurrent Increase of AMPK Phosphorylation
AMPK has been previously implicated in the regulation of
glucose uptake (review in [24]). We examined whether AMPK can
mediate the action of leptin in the intestine. We found that luminal
leptin alone or in association with fructose significantly increased
phosphorylation of the catalytic a subunit of AMPK (fig. 3, B).
Indeed, fructose or leptin (1 nM) added into the lumen increases
phosphorylation of AMPKa by 2-fold as compared to controls
(fig. 3, B). Interestingly, treatment with a combination of fructose
and leptin gave levels of phosphorylated AMPKa 3-fold higher
than those observed in controls (P,0.05). This increased
phosphorylation was similar to that induced by AICAR, a
pharmacological activator of AMPK. These data argue for the
involvement of the a subunit of AMPK in mediating the effects of
leptin.
We next used AMPKa2 knockout (AMPKa22/2) mice to
further study the role of a2 subunit of AMPK in the effects of
leptin. Histological analysis showed that there was no difference in
the architecture of jejunum mucosa between WT and AMPKa2
2/2 mice (fig. 3, C, D). However, Western blot analysis of
extracts from jejunum of AMPKa2 2/2 mice (fig. 3, E) showed
that levels of GLUT2 and GLUT5 proteins were three times lower
than in the jejunum of WT mice (P,0.001). In parallel, SGLT-1
transporters were increased in AMPKa22/2 by 2-fold as
compared to WT mice (Text S1, fig. S2). The transport activity
of SGLT-1 was determined in Ussing chamber. The addition of
10 mM glucose into the mucosal bath led to a rapid and significant
rise in the short circuit current (Isc) which was 2.3 times higher in
jejunum from AMPKa22/2 mice than in jejunum from WT
Figure 3. Luminal leptin phosphorylates PKCbII and AMPKa in
the jejunum. A, A representative immunoblot (5 different prepara-
tions of BBM) of phosphorylated and total PKCbII from rat jejunum
loops treated with or without luminal leptin in association with or
without 30 mM fructose. The data of densitometric analysis of the blots
are expressed as a ratio of phosphorylated PKCbII to total PKCbII. B, a
representative immunoblot (4 separate experiments) of phosphorylated
and total AMPK from mucosa extracts of rat jejunum loops incubated
with or without (CTRL) 1 nM leptin in association without or with
30 mM fructose. 5-aminoimidazole-4-carboxamide riboside (2.5 mM
AICAR) was used as control. Data of densitometric analysis are
expressed as a ratio of phosphorylated AMPKa to total AMPK.
*P,0.05, ** P,0.01 and *** P,0.001 vs. CTRL. C, D, histological
analysis of jejunum sections from AMPKa22/2 and WT mice stained
with hematoxylin-eosin (scale bar=20 mm). E, representative immuno-
blots of GLUT2 and GLUT5 proteins in extracts from jejunum mucosa
from AMPKa22/2 and WT mice. Data of densitometric analysis of the
blots are expressed as relative protein levels. Each column represent the
mean6SEM of n=5 mice in each group. *** P,0.001 vs WT.
doi:10.1371/journal.pone.0007935.g003
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activity/expression of sugar transporters in the small intestine
through mechanisms requiring the a2 subunit of AMPK.
Oral Leptin Increases GLUT2 and GLUT5 mRNA Levels in
the Jejunum
We have determined whether administration of 3 ng/g leptin to
mice by gavage either alone or with fructose, could replenish the
cytosolic pool of transporters by increasing the levels of their
mRNA levels. This dose of leptin was chosen from our pilot
experiments showing that the peptide given by gavage generates
levels of leptin similar to those detected in the stomach after meal.
Moreover, 15 min after gavage, 70% of the peptide was detected
in the small intestine representing a concentration sufficient to
activate leptin receptors.
As shown in fig. 4A, mice receiving leptin by gavage, had 1.6-
fold and 2 -fold higher levels of GLUT2 and GLUT5 mRNAs in
the jejunum respectively, than control mice receiving saline. Oral
load of fructose increased by 3-fold (P,0.01 vs CTRL) and 5-fold
(P,0.01 vs CTRL) GLUT2 and GLUT5 mRNA levels,
respectively, consistent with previous reports [25,26]. Leptin given
together with oral fructose significantly enhanced this effect,
Figure 4. Acute and chronic leptin administration increase basal and fructose-stimulated GLUT2 and GLUT5 mRNA. A, for acute
studies, 16-hour deprived fasted mice receiving oral administration of saline (CTRL), 3 ng/g murine leptin, fructose (2 g/kg) or fructose in combination
with leptin. They were sacrified 4 hours later, and total RNA was extracted from the jejunum mucosa for qRT-PCR analysis in duplicate using specific
oligonucleotides for GLUT2 and GLUT5 genes. Results are means6SEM for 8 mice in each group. B, for chronic studies, mice fed a standard diet (SD)
or a high-calorie diet (HFD), received saline (CTRL) or 3 ng/g leptin, administered daily by gavage for 7 days. Mice were killed on day 8 and total RNA
was extracted from jejunum mucosa for qRT-PCR analysis. Results are means6SEM for 8 mice in each study and each group. * P,0.05; ** P,0.01 and
*** P,0.001 vs CTRL. B insert, representative immunoblots of GLUT2 and GLUT5 proteins from jejunum extracts of mice fed a SD and a high-calorie
diet (HFD) showing increased amount GLUT2 and GLUT5 proteins when mice were fed a HFD in comparison to those fed a SD.
doi:10.1371/journal.pone.0007935.g004
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fructose) and those of GLUT5 by a factor of 7 (vs. 5-fold).
This acute effect of leptin was still observed after 7 days of daily
treatment of the mice with leptin (fig. 4, B) and was exacerbated in
mice fed on a HFD. In mice fed with HFD for 7 days in
comparison to those fed with ND, the levels GLUT2 and GLUT5
proteins are significantly increased (fig. 4, B insert). Moreover,
treatment of HFD mice with leptin by gavage, led to a dramatic
increase in the mRNA levels with a 6-fold increase in GLUT2
mRNA (P,0.001) and a 9-fold increase in GLUT5 mRNA
(P,0.001) in vehicle-treated mice (fig. 4, B).
The Actions of Leptin Are Followed by Changes in Blood
Fructose and Glucose Levels
As expected, oral administration of radiolabelled
14C-fructose
induced a time-dependent increase of
14C fructose in blood in
parallel with glucose (fig. 5, A). When fructose was given in
combination with leptin, a rapid and significant increase in
fructose-induced hyperglycaemia occurred as soon as 15 min. The
+20% increase (P,0.05 vs. fructose) reached at 15 min was
maintained over the 120 min period. At that time, the amount of
14C fructose detected in the liver was significantly 2-fold higher
with fructose in combination with leptin than with fructose alone
(fig. 5, B).
This enhancement of fructose-induced glycaemia by leptin
given orally was dependent on the amount of ingested fructose.
Indeed, when the same dose of leptin (3 ng/g) was combined with
low amount of fructose (1 g/kg), an increase in fructose-induced
hyperglycaemia was also observed but, at levels significantly lower
than those levels seen with 2 g/kg fructose (data not shown). The
areas under curves for both low (1 g/kg) and the high (2 g/kg)
fructose (fig. 5, C insert) were significantly increased when leptin
Figure 5. Luminal leptin increases fructose-induced hyperglycaemia and hepatic content of fructose. Changes in plasma glucose levels
(A) and in hepatic content of fructose (B). A solution of fructose (2 g/kg) containing radiolabelled [
14C]-fructose was given by gavage without
(control) or with 3 ng/g leptin to 16-hour fasted mice. Before starting the oral fructose tolerance test (OFTT), blood samples were taken from the tail
and glucose levels was determined using Accu-Chek. At 120 minutes, the radioactivity in liver was counted and used to calculate the hepatic content
fructose. C, changes in blood glucose levels as a function of plasma insulin levels. Fifteen minutes after oral administration of fructose (2 g/kg)
without (control) or with 3 ng/g leptin to 16-hour fasted mice, blood was collected as described in Materials and Methods for determination of plasma
glucose and insulin levels. C insert, are the measured area under curves at time 60 min after oral load of fructose (1 or 2 g/kg) without or with 3 ng/
g leptin. Each column represents the mean6SEM of n=8 mice for saline and leptin, n=12 for each amount of fructose and fructose+leptin. * P,0.05
vs. saline; # P,0.05 vs fructose.
doi:10.1371/journal.pone.0007935.g005
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15 min after administration of fructose alone or in combination
with leptin, significantly increased in parallel with the levels of
glucose (fig. 5, C). The increase in circulating levels of glucose and
in liver fructose content after oral fructose either alone or in
combination with leptin, suggests a possible enterocyte and/or
liver production of glucose. To verify these possibilities, we
quantified mRNA levels of some key enzymes involved in
gluconeogenesis.
Changes in mRNA of Key Gluconeogenesis Enzymes
Previous studies have shown that, together with increased
GLUT5 mRNA, the expression of genes encoding gluconeogenic
enzymes also increased significantly after luminal fructose [27].
We found that oral load of fructose induced a significant increase
in the levels of FK, F1,6BPase and G6Pase mRNAs and did not
significantly affect PEPCK mRNA levels in jejunum and the liver
(fig. 6). Leptin given by gavage did not significantly modify mRNA
levels of these enzymes. When combined with oral fructose, leptin
potentiated fructose-induced increase in the levels of FK,
F1,6BPase and G6Pase mRNA both in the intestine and the liver
(fig. 6). These changes in F1,6BPase and G6Pase mRNA levels
paralleled those of their protein levels in the intestine and the liver
(fig. 6 insert).
Changes in mRNA levels of Some Enzymes of Lipid
Metabolism
In addition to the mild hyperglycaemia induced by fructose, the
levels of blood triglycerides were significantly increased (Table 1).
Thus, we first questioned whether oral load of fructose without or
with leptin could modify the expression of Fasting-induced
adipocyte factor (Fiaf). The Fiaf gene encodes a secreted
lipoprotein lipase (LPL) inhibitor that is also produced in intestinal
epithelium and the liver [28]. We found unexpectedly that oral
load of fructose induced a significant 4-fold (P,0.01 vs. CTRL)
and 3-fold (P,0.01 vs. CTRL) reduction in intestinal and hepatic
Fiaf mRNA levels, respectively (fig. 7, A, B). When leptin alone
was given orally, there were no significant changes in the levels of
Fiaf mRNA both in intestine and the liver. However, when
combined with fructose, leptin exacerbated fructose-induced
decrease in Fiaf mRNA levels. This suppression of Fiaf mRNA
levels is likely to result in an increase in LPL activity, an enzyme
mediating the rate-limiting step for triglyceride-derived fatty acid
production.
Second, given that fructose consumption can promote lipogen-
esis in liver, the main site of fructose metabolism, the mRNA levels
of SREBP-1c (a transcription factor targeting lipogenic genes) and
two lipogenic enzymes were examined specifically in the liver. As
shown in fig. 7C, levels of SREBP-1c mRNA were twice as high in
mice receiving oral fructose alone than in controls (P,0.01 vs.
CTRL). This effect was more potent when combined with leptin
(P,0.05 vs. fructose alone). In parallel, hepatic ACC-1 and FAS
mRNA levels (fig. 7, D, E) significantly increased and this increase
was boosted when leptin was added (P,0.05 vs. fructose). The
changes in the levels of ACC-1 and FAS mRNA paralleled those
of ACC-1 and FAS proteins (fig. 8, A, C).
To further assess the impact of increased expression of ACC-1,
phosphorylation of the enzyme was determined as an index of
activity. As shown in fig. 8B, the phosphorylation of ACC-1
protein significantly decreased by 2-fold after oral load of fructose
and by 3-fold when combined with leptin, indicating an increased
ACC-1 activity. It is noteworthy that oral leptin alone significantly
increased by 3-fold the phosphorylation of ACC-1 indicating that
leptin given orally inactivates ACC-1 in the liver.
Figure 6. Leptin given orally potentiates fructose-induced
mRNA levels of enzymes involved in glucose metabolism in
intestine and the liver. Total RNA was extracted from jejunum
mucosa and the liver, 4 hours after oral administration of saline (CTRL)
or 3 ng/g leptin, oral fructose (2 g/kg) or both, in fasted mice. Q-RT PCR
analysis was performed in duplicate using specific oligonucleotides for
fructokinase, F1,6BPase, G6Pase and PEPCK genes, left columns:
jejunum, right columns: liver. Inserts are representative immunoblots
of F1,6BPase, glucose-6-phosphatase (G6Pase). Results are means6SEM
for 6 mice in each group. * P,0.05 and ** P,0.01 vs. CTRL.
doi:10.1371/journal.pone.0007935.g006
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Leptin in Gastric Juice without Affecting Plasma Leptin
Levels
To determine the physiological relevance of these results, we
analyzed the effects of oral fructose on luminal contents of leptin
from stomach and the small intestine in fasted mice (fig. 9).
Unexpectedly, oral load of fructose but not galactose, resulted in a
dramatic 10-fold increase in basal leptin content in gastric juice
(P,0.05 vs CTRL). This effect was rapid and seen as early as
15 min. This rapid increase was similar to that induced by i.p.
administration of CCK-8 (used as a positive control) in agreement
with our previous findings in rats [10]. It is noteworthy that during
this 15-min period, the increase in gastric leptin output in response
to fructose was not associated with significant change in plasma
leptin levels (fig. 9). However, 4 hours after oral fructose, the levels
of plasma leptin were significantly increased (Table 1) probably
reflecting the contribution of fat tissues.
Discussion
The small intestine is the primary site of absorption of dietary
sugars. Thus, a better understanding of the regulatory mechanisms
involved in their entry and exit from intestinal epithelium to blood,
is of great interest. In this combined in vivo and in vitro approaches,
we showed that intestinal GLUT2 and GLUT5 transporters are
direct targets of luminal leptin detected in the intestinal lumen and
originating from the stomach. Indeed, introduction of exogenous
leptin into intestinal lumen resulted in an up-regulation of
transepithelial transport of fructose, a concurrent potentiation of
circulating levels of glucose, and an increase in fructose content in
the liver. These effects were accompanied by increased circulating
levels of triglycerides, suppression of Fiaf expression both in
intestinal epithelium and the liver, and by induction of hepatic
SREBP-1c transcription factor, targeting genes in the fatty acid
biosynthesis pathway. These findings may have physiological
implications. Thus, we demonstrated for the first time that oral
load of fructose, but not galactose rapidly induces release of gastric
leptin which enters the intestine at a concentration compatible
with the activation of leptin receptors. Collectively, these data
sustain that in the small intestine, a positive regulatory control loop
exists between gut leptin and two transporters: the specific
GLUT5 fructose transporter and the apical GLUT2 which is
active in conditions of high concentrations of glucose/galactose
and which has a minor participation in fructose transport. This
regulatory loop appears to be connected to metabolic functions in
the liver.
Firstly, we showed that mucosal leptin increases GLUT2 and
GLUT5 transporter activity as well as insertion of GLUT2 and
GLUT5 in the brush-border membrane (BBM). These changes
were leptin-receptor specific since they were blocked by leptin
antagonist and correlated with the phosphorylation/activation of
PKCbII at the BBM. This activation of PKCbII enhanced the
insertion of GLUT2/5 and reduced the insertion of the energy-
dependent SGLT1 transporters into the brush-border membrane,
consistent with previous data [2,9,23]. The findings have clear
physiological implications: immediately after a meal, a high local
concentration of sugars is generated at the surface of the brush-
border by disaccharidases. The released gastric leptin [10] enters
the lumen of the intestine [12,30], where it may then up-regulate
GLUT2/GLUT5 transporter activity to match dietary intake. The
intracellular mechanisms of such a rapid regulation of absorption
by luminal leptin involve the activation of AMPKa which is
known to play a central role in regulating glucose uptake (review in
[24]). In this context, we showed that luminally acting leptin
phosphorylates/activates AMPKa in the intestine consistent with
previous data reporting similar findings in other biological systems
i.e. liver, hypothalamus, muscles [29,31–33]. Interestingly, we
found that leptin given orally can boost the fructose activation of
AMPKa leading to increased GLUT2/GLUT5 transport activi-
ties, indicating that these transporters are responsive to AMPK
activation [34]. We further elucidated a role of AMPK in the
leptin regulation of intestinal hexoses transporters by using
AMPKa2 KO mice [29]. We found that deletion of the catalytic
subunit a2, which does not alter the architecture of the jejunum,
potently lowered levels of GLUT2 and GLUT5 and elevated levels
of SGLT1. This increase in SGLT1 levels correlated with an
increase in its activity, as measured by glucose-induced Isc using
the Ussing chamber (fig. S1), and might represent a compensatory
effect in the process of sugar absorption. Alternatively, the reduced
expression of GLUT2/GLUT5 and the increased SGLT1
expression in AMPKa2 KO mice could reflect a differential
regulation of these transporters by AMPKa2 as reported by
Walker and coworkers [34] showing that activation of AMPK
results in an up-regulation of GLUT2 and a concurrent down-
regulation of SGLT-1. Moreover, in the jejunum of WT mice,
luminal leptin inhibited SGLT1-mediated glucose transport which
is in line with our previous findings [9]. However, we did not
observe this effect in AMPKa2 KO jejunum, suggesting that leptin
Table 1. Plasma levels in 18-hour fasted mice receiving orally saline (CTRL), fructose (2 g/kg), leptin (3 ng/g) or fructose with
leptin.
CTRL Fructose 2 g/kg Leptin 3 ng/kg Fructose + Leptin
Plasma leptin (ng/mL) 1.5060.35 2.8560.37* 1.4260.20 2.8160.21
Plasma insulin (ng/mL 0.2160.02 0.5060.13* 0.2760.05 0.5960.12*
Blood glucose mmol/L 2.6060.25 4.8560.25 3.7160.28* 5.7860.22**#
Blood triglycerides mmol/L 0.9560.06 1.3260.16* 0.6060.04 * 1.4560.13
HDL cholesterol mmol/L 1.5460.22 1.2460.32 1.5760.11 1.3760.20
Total cholesterol mmol/L 1.8860.25 3.2160.28* 2.0760.21 2.9760.24*
Mice were killed 4 hours after gavage, blood was collected, processed as described in Material and Methods and used to determine biochemical parameters.
Data are expressed as mean6SEM of n=8 mice per group. One-way ANOVA followed by a multiple comparisons Tukey t-test were used for statistical analysis.
*P,0.05,
**P,0.01 vs. CTRL;
#P,0.05 vs. fructose alone.
doi:10.1371/journal.pone.0007935.t001
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catalytic a2 subunit of AMPK for this inhibitory effect. Our data
can be compared to previous findings showing that activation of
AMPK in murine jejunum tissues, increases glucose uptake which
can be attributed to an increased amount of GLUT2 in the BBM
[34].
On the other hand, in vivo luminal fructose increases GLUT2
and GLUT5 mRNA levels as reported earlier [4,27] and this effect
is potentiated by leptin given orally. This suggests that luminal
leptin can replenish the pool of the transporters by inducing gene
transcription. The in vivo dose of leptin was comparable to the
doses detected in gastric juice (0.9 to 1.2 nmol/L) in response to
fructose as well as the levels of leptin detected in intestinal juice
(0.7 nmol/L). These concentrations of leptin can activate leptin
receptor [35,36]. Our demonstration that the actions of leptin
require active jejunal leptin receptors, led us to propose a two-step
mode of action for luminal leptin regulation of sugars transport,
involving a rapid recruitment of GLUT2/GLUT5 to the BBM to
deal with the inflow of dietary sugars during a meal, followed by
transcription of the corresponding genes, allowing the reconstitu-
tion of the cytosolic pool of transporters. These data are
summarized in fig. S3.
Figure 7. Changes in Fiaf, hepatic SREBP-1c, ACC-1 and FAS mRNA in response to oral administration of fructose or leptin or both.
Total RNA was extracted from jejunum mucosa and the liver, 4 hours after oral administration of saline (CTRL), leptin (3 ng/g), oral fructose (2 g/kg)
or both, in fasted mice. QRT-PCR analysis was performed in duplicate using specific oligonucleotides targeting genes encoding (A, B) fasting-induced
adipocyte factor (Fiaf), (C) liver SREBP-1c, (D) liver ACC-1 and (E) liver FAS. Results are means6SEM for 6 mice in each group are expressed as mRNA
levels relative expression. * P,0.05; ** P,0.01 vs CTRL.
doi:10.1371/journal.pone.0007935.g007
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markedly increased when mice fed with a HFD received
chronically leptin given orally. This suggests that gut leptin might
be a key molecule for the enterocyte in adapting the levels of
carbohydrate transporters to the diet. This is in line with recent
observations showing that, on an already potent obesity-inducing
hypercaloric diet, fructose induces leptin-resistance leading to
pronounced susceptibility to increased weight gain [37,38].
This leptin up-regulation of GLUT2/GLUT5 affects in vivo
circulating levels of glucose and triglycerides. Indeed, oral leptin
enhanced fructose-induced mild hyperglycaemia and the size of
this effect is dependent on the amount of fructose absorbed. As a
consequence of increased hyperglycaemia, plasma insulin levels
increased to adapt glucose uptake by the different tissues.
Moreover, all the changes occurring after oral leptin are not
associated with changes in plasma leptin levels, indicating that the
primary site of action of oral leptin is within the gut mucosa.
In addition to observing the increase in plasma glucose levels
after an oral load of fructose, the majority of the absorbed fructose
appears in the blood and liver, the main site of fructose
metabolism. These findings were consistent with data from studies
in rodents and humans [39]. Thus, the increased plasma glucose
could originate from fructose metabolism in the liver and possibly
from enterocytes. Fructose is metabolised mainly in the liver
through two alternative pathways: the fructose 1-phosphate
pathway, involving fructokinase, and/or the fructose 6-phosphate
pathways. In the enterocyte, fructose is metabolised by fructokin-
ase through the fructose 1-phosphate pathway. As for the liver and
kidney, the small intestine expresses gluconeogenesis genes such as
those encoding G6Pase and PEPCK [40]. The transcription of
these gluconeogenic genes is tightly controlled in the liver by
substrates and various hormones [41]. Here, we demonstrate a
potentiation by oral leptin of fructose-induced mRNA levels of
FK-, F1,6BPase- and G6Pase-encoding genes in the liver and the
jejunum. The observed increase in these enzymes mRNA is
causally linked to the amount of fructose absorbed; indeed oral
leptin alone fails to affect the levels of these enzymes. Thus, as in
the liver, glucose produced by the enterocyte may contribute
partly to fructose-induced hyperglycemia consistent with a
neoglucogenic status for the small intestine [42].
The leptin stimulation of GLUT5 fructose transport is
associated with the unexpected reduction of the levels of Fiaf
mRNA in both the intestine and the liver. Fiaf is a gene which
encodes a physiologically relevant circulating inhibitor of LPL
[28], an enzyme that promotes storage of triglycerides [43]. This
reduction of intestinal and hepatic levels of Fiaf mRNA, is
Figure 8. Changes in hepatic ACC-1 and FAS proteins in response to fructose, leptin or both given orally. Proteins were extracted from
jejunum mucosa and the liver, 4 hours after oral administration of saline, leptin (3 ng/g), oral fructose (2 g/kg) or both, in fasted mice. Representative
immunoblots of phosphorylated ACC-1, total ACC-1, FAS and b-actin protein in liver extracts. Lane 1: control; lane 2: Fructose 2 g/kg: lane 3: leptin
3 ng/g; lane 4: fructose in combination with leptin. Results of densitometric analysis are expressed as mean6SEM of 6 mice in each group. ** P,0.01
and *** P,0.01 vs. CTRL.
doi:10.1371/journal.pone.0007935.g008
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Indeed, leptin alone given orally enhances Fiaf mRNA levels,
implying that fructose is the primary signal controlling the levels of
Fiaf mRNA. The suppression of Fiaf may increase LPL activity
and thus activates storage of triglycerides in tissues such as the
liver. Our data are reminiscent of those recently demonstrating an
enterocyte-specific suppression of Fiaf by the gut microbiota
leading to induction of de novo hepatic lipogenesis, probably
through the increased conversion of dietary polysaccharides into
monosaccharides [44]. The fact that leptin potentiates the fructose
induction of SREBP-1c, a transcription factor targeting lipogenic
genes in the liver [45,46], strengthens this hypothesis. Interesting-
ly, this leptin potentiation of fructose-induced SREBP-1c was
associated with increased expression and activation of ACC-1, the
key regulatory enzyme of fatty acid biosynthesis. The activation
ACC-1 is expected to elevate the levels of malonyl-CoA in the
liver. The concurrent increased expression of hepatic FAS which
plays a central role in de novo lipogenesis, catalyzing reactions steps
in the conversion of malonyl-CoA to palmitate [47,48], may also
indicate increased levels of palmitate. The surprising capacity of
leptin given orally to phosphorylate/inactivate ACC-1 in the liver
argues for a beneficial effect on the liver. This effect of gut leptin is
quite different from the results showing that intracerebroventri-
cular injection of leptin activates hypothalamic ACC, up-regulates
the levels of malonyl-CoA and concomitantly inhibits AMPK [49].
We have no clear explanation for these discrepancies but
undoubtedly they need to be clarified. The effects of leptin given
orally on hepatic metabolic functions could be of great importance
in terms of pharmacological manipulation of the expression of
these key enzymes, but the mechanisms involved need to be
elucidated. Actually, we cannot exclude that leptin given by oral
route, could enter the liver in sufficient quantity to affect the
hepatic expression of genes encoding key metabolic enzymes.
Indeed, we demonstrated that oral fructose but not galactose,
triggers a rapid and dramatic secretion of gastric leptin in gastric
juice which is found at levels compatible with activation of leptin
receptors in the intestinal lumen. These findings are of great
interest in light with the recent data demonstrating that consuming
fructose-sweetened, and not glucose sweetened, beverages increas-
es de novo lipogenesis and increases visceral adiposity in overweight
and obese adults [50].
Our data sustain the existence of a positive regulatory control
loop between gut leptin and fructose, in which fructose triggers the
release of gastric leptin which in turn up-regulates GLUT2/
GLUT5 leading to increase fructose absorption and changes in
some metabolic functions in the liver. We have summarized these
intestine-liver cross talks in fig. 10. This regulatory control loop
appears to be a new mechanism (possibly pathogenic) by which
fructose consumption rapidly becomes highly lipogenic and
deleterious by increasing adiposity. Although rodents may not
have identical metabolic pathways to those of humans, our
findings provide basis for introducing further nutritional recom-
mendations relative to excess consumption of fructose.
Materials and Methods
Animals
AnimalsusedforourexperimentsweremaleWistarrats,C57BL/
6J mice 6-8 weeks old (Elevage Janvier, Le genest-St-Isle, France)
and AMPKa2 catalytic subunit gene knockout (AMPKa2
2/2)
10–12 weeks-old mice [29]. All procedures were performed in
accordance with the principles and guidelines established by the
European Convention for the Protection of Laboratory concerning
care and the use of laboratory and with the authorization order Nu
B75-18-02 delivered by Ministry of Agriculture and Prefecture of
Paris, France.
Transport of Galactose and Fructose in the Rat Jejunal
Loop In Vitro
The animals were killed, and the transport was monitored using
the in vitro jejunal loop model. Briefly, a 5-cm segment of jejunum
was filled with a Krebs buffer pH 6 containing 100 mM D-
galactose or 30 mM fructose added with 0.1 mCi/mL [D-
14C]-
galactose or [
14C]-fructose (specific activity 57 and 267 mCi/
mmoL, respectively) in absence and the presence of murine leptin
(PeproTech Neuilly/Seine France). CCK-8 (Sigma Chemicals, St
Louis Mo) was added in the bath solution (serosal side) as a positive
control. The effect of leptin on transport of [
14C]-mannitol as non-
transported substrate was also determined.
Figure 9. Release of leptin in gastric juice in response to oral
load of fructose or galactose. Changes in the amount of leptin
released in the gastric juice and in plasma in mice fasted overnight and
receiving an oral load of saline (CTRL), fructose [Fruct. 2 g/kg)],
galactose (Gal. 6 g/kg) or intraperitoneal injection of 10 ng/g CCK-8.
Leptin immunoreactivity was determined by RIA in 15-min collected
juice from the stomach as described in Materials & Methods. Data are
expressed as the mean6SEM of n=6 in control group and n=5 in each
other group. *P,0.05 and ***P,0.01 vs CTRL.
doi:10.1371/journal.pone.0007935.g009
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D40A/F41A mutein (1, 10 nM) an antagonist of leptin-receptor
[20] were used, the jejunum segments were preincubated for
5 min before addition of galactose or fructose solution. The
incubation medium was sampled and radioactivity was counted.
Apparent permeability (Papp) was used to assess mucosal to serosal
transport according to the following equation Papp=(dQ/dt).(V/
Q0.A) where V is the volume of the incubation medium, A is the
area of the loop, Q0 is the total radiolabelled galactose or fructose
introduced into the loop and dQ/dt is the flux across the jejunum
loop.
Western Blot Analysis of GLUT2 and GLUT5 in Membrane
Preparations
16-hour fasted rats were anesthetized by pentobarbital and
laparotomized for in situ experiments. Jejunal loops were isolated in
situ and filled with a Krebs buffer without or with leptin. After
3 min of incubation, these loops were injected with 100 mM
unlabelled galactose or 30 mM fructose. After a further 5 min
incubation, the loops were removed, opened along the mesenteric
border and the mucosa was scrapped off on ice. Total proteins and
brush border membranes (BBM) were prepared in PBS containing
protease and phosphatase inhibitors (Sigma Chemicals, St Louis
Mo, USA) as previously described [9] and enrichment was
estimated by determination of alkaline phosphatase activity (20-
fold increase of activity in BBM). Protein concentration was
quantified using the BCA protein assay Kit (Pierce, Rockford Il,
USA) and used for western blot analysis. Solubilised proteins (50–
100 mg) were resolved on SDS-PAGE in gels containing 8–10%
acrylamide, transferred to nitrocellulose membranes and subjected
to immunoblotting with rabbit polyclonal antibodies anti-GLUT2
(sc-9117) and anti-GLUT5 (sc-9117) [Santa Cruz Biotechnology,
Inc., CA, USA). Immune complexes were detected by enhanced
chemiluminescence (ECL; Perkin Elmer Boston, MA, USA). The
intensity of the specific immunoreactive bands was quantified with
Figure 10. Schematic view of the regulatory control loop between gut leptin and fructose transporters. Ingestion of fructose increased
the release of gastric leptin which enters together with fructose the intestine. The concentrations of leptin detected in intestinal juice are suitable
with activation of leptin receptors. This luminal leptin operates through leptin receptor (Ob-R) to increase the clearance of fructose from the intestinal
lumen predominantly via the brush border GLUT5 transporter. Fructose and glucose exit the enterocyte through the basolateral GLUT2 transporter
into the blood and are delivered to various organs including the liver. Fructose enters into the liver, induces SREBP-1c a transcription factor targeting
genes in the lipogenic program. This cluster of events which are amplified by gut leptin is likely to provide the mechanism for rapidly acquired
adiposity. FK: fructokinase, G6Pase: glucose-6-phosphatase, Fiaf: Fasting-induced adipocyte factor, TG triglycerides, SBREP-1c: Sterol Regulatory
Element Binding Protein-1c; ACC-1 Acetyl-coA Carboxylase isoform 1, FAS, fatty acid synthase.
doi:10.1371/journal.pone.0007935.g010
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results were expressed in relation to control, and the mean value of
controls was arbitrarily set to 1 and used for calculations.
Glucose Transporters in the Jejunum of AMPKa2
2/2 Mice
AMPKa2
2/2 mice were killed by cervical dislocation and the
jejunum was removed for histological analysis by routine tech-
niques. Sections (4 mm) were mounted on glass slides, stained with
hematoxylin-eosin (H&E) and examined by light microscopy.
Concerning Western blot analysis, proteins were extracted from
jejunal mucosa scrapings as described above. For functional studies,
a third jejunum fragment was used for SGLT-1 mediated glucose
transport using the Ussing chamber as described in Figure S2.
Acute Effects of Leptin on Jejunal GLUT2 and GLUT5
mRNA Levels
18-hour fasted mice were treated with vehicle or 3 ng/g murine
leptin administered by gavage. Four hours later, blood was
collected from the retro-orbital sinus with heparinized capillary
Pasteur pipettes, centrifuged and the plasma was stored at 220uC.
Mice were sacrificed, a fragment of their liver was removed and
immediately frozen in liquid nitrogen. The jejunum was removed,
rinsed and the mucosa was scrapped off and immediately frozen.
All the collected tissues were stored at 280uC until use for
extraction of total RNA for qRT-PCR analysis and for extraction
of total protein for western blot analysis as described above, using
the following antibodies: rabbit anti-fructose-1,6-bisphosphatase
(anti-FBPase) polyclonal antibody (sc-66946), rabbit anti-FAS
polyclonal antibody (sc-1023), goat anti-glucose-6-phosphatase
(anti-G6Pase) polyclonal antibody (sc-33839) purchased from
Santa Cruz (Santa Cruz, CA) and rabbit purified anti-ACC-1
monoclonal antibody and rabbit purified anti-phospho ACC-1
(Ser79) polyclonal antibody were purchased from Millipore
(Millipore SAS, Molsheim, France).
Chronic Effects of Leptin on GLUT2 and GLUT5 mRNA
Levels in Mice Fed a High Fat Diet (HFD)
Experiments were performed on 6-week-old male C57BL/6J
purchased from Janvier (Le-Genest-St-Isle, France) that were fed
ad libitum a standard diet (SD: A04 biscuits; UAR, Villemoisson-
sur-Orge, France) or a high-fat high-sucrose diet (HFD) purchased
from SAFE, Augy, France. The HFD diet includes 36% fat, 35%
carbohydrates mainly saccharose and 18% protein [51]. Mice fed
on a SD or a HFD were treated every day with 3 ng/g leptin for 7
days by gavage. At day 8, blood was collected from non-fasted
mice, the jejunum mucosa was scrapped off as described above
and used for qRT-PCR and western blot analysis of transporters.
RNA Preparation and Real-Time PCR Analysis (qRT-PCR)
Total RNA was extracted from the jejunal mucosa samples or
liver fragments with the Trizol reagent (Qiagen). Quantitative RT-
PCR was carried out on Light Cycler System 480 (Roche
Diagnostics) as previously described. The oligonucleotides primers
sequences of the mouse genes studied (Table 2) were designed with
Oligo 4 software and synthesized by Eurogentec (France).
Oral Fructose Tolerance Test
Three sets of experiments were conducted with the 16-hour
fasted mice. In the first set of experiments, we determined whether
leptin could increase fructose absorption in conscious animals. To
this end, mice were given an oral load of 2 g fructose per kg of
body weight added with 0.1 mCi radiolabelled [
14C]-fructose
without (control) or with 3 ng/g leptin. Before starting the oral
fructose tolerance test (OFTT), blood samples were taken from the
tail and blood glucose levels were determined (ACCU-CHEK;
Roche Diagnostics, Meylan, France). The bleeds were further
taken at 15, 30, 60, 90 and 120 min after administration. At 120
minutes, blood was collected, mice were sacrificed and segments of
jejunum and the liver were removed. The radioactivity was
counted and used to calculate the amount of fructose in these
compartments. For jejunum and the liver, the data were expressed
as moles of fructose per gram wet tissue.
The second set of experiments was designed to determine if the
effects of leptin depend on the amount of ingested fructose. Mice
were given an oral load of 1 g or 2 g unlabelled D-fructose per kg
of body weight without (control) or with 3 ng/g leptin. Blood
samples were taken and blood glucose levels were determined as
mentioned above. These experiments were performed with 16
individual animals, each animal being its own control. The
animals were allowed to recovery during 72 hours between two
experiments.
The third set of experiments, fasted mice were divided into four
groups and treated without or with fructose in the presence or the
absence of 3 ng/g leptin. Fifteen minutes later, blood was drawn
from the retro-orbital sinus with heparinised capillary Pasteur
pipettes, centrifuged and the plasma was stored at 220uC until
determination of insulin levels by RIA.
Table 2. Sequences of primers used for real time quantitative PCR.
Gene name Accession number Primer sequences
Facilitative glucose transporter number 2 (GLUT2) NM_031197 F59-ctgctcttctgtccagaaagc-39 R59-tggtgacatcctcagttcctc-39
Facilitative glucose/fructose transporter number 5 (GLUT5) NM_019741 F59-gaagacacactgagccgtgga-39 R59-cctttcttcagcagggaagtgtc-39
Sodium/glucose co-transporter member 1 (SGLT1) NM_019810 F 59-gacatcccagaggactccaa-39 R59-accactgtcctccacaaagg-39
Sterol regulatory element binding protein transcription
factor 1c (SREBP-1c)
NM_011480 F59-atcggcgcggaagctgtcgg-39 R59-actgtccttggttgttgatgagt-39
Acetyl-CoA carboxylase 1 (ACC-1) NM_133360 F59-caatcttcctgcagcacagctcc-39 R5-cccaaggagataccccatacatc-39
Phosphoenolpyruvate carboxykinase (PEPCK) NM_011044 F59-gagtagcacagagaacag-39 R5-tgactttgaagtggaaccca-39
Ribosomal RNA (18S) NM_111457 F59-ccctgccctttgtacacacc-39 R59-gatccgagggcgctcacta-39
Glucose-6-phosphatase (G6Pase) NM_008061 F59-cacaccaccttctctatcac-39 R5-gttgcctaccagacacagc-39
Fructokinase (FK) NM_008439 F59-tttgtgtccattccccaaat-39 R59-gtggactcccagttctgag-39
Fasting-induced adipocyte factor (FIAF) NM_020581 F59-caggctaccaccctgttgat-39 R59-ctttgtccacaagacgcaga-39
doi:10.1371/journal.pone.0007935.t002
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Stomach and the Intestine
18-hour fasted mice were treated by gavage with saline, fructose
(1 g and 2 g/kg body weight), 6 g/kg galactose or with
intraperitoneal injection of 10 ng/g CCK-8 as positive control.
Fifteen minutes later, blood was drawn from the retro-orbital
sinus, centrifuged and the plasma stored at 220uC until RIA of
leptin. Mice were sacrificed, their stomachs and their small
intestines (from duodenum to ileum) were removed and then
flushed each with 1 ml of PBS buffer containing 500 UI/ml
aprotinin; the luminal contents were collected on ice, centrifuged
at 3,000 rpm for 10 min and the supernatants were used for a
leptin determination by a RIA.
Statistical Analysis
All values are expressed as means6SEM. One- or Two-way
ANOVA followed by Tukey-Kramer multiple comparisons post-
test was used to compare the groups. Statistical analysis was
performed with Graph Pad Prism version 3.0 for Windows (Graph
Pad Software, San Diego, CA, USA). Values of P,0.05 were
considered statistically significant for all analyses.
Supporting Information
Text S1 Luminal leptin increases GLUT2-mediated galactose
transport and increases galactose levels in blood, in vivo in the rat.
AMPKa2 KO mice had an increased expression and activity of
SGLT1 in the jejunum.
Found at: doi:10.1371/journal.pone.0007935.s001 (0.04 MB
DOC)
Figure S1 Appearance of radiolabelled [14C]-galactose in blood
after introduction into the jejunum. A solution of 100 mM
galactose added with 0.1 mCi [14C]-galactose solution with saline
or with 5 nM leptin alone or in association with 10 nM L39A/
D40A/F41A leptin mutein (L39), was injected into jejunal loops
from fasted rats fitted with carotid catheter as previously described
[14]. Plasma galactose was significantly higher after treatment with
luminal leptin than after treatment with vehicle. Results show
incremental area under the curves (insert).*P,0.05 vs. saline, #
vs. leptin.
Found at: doi:10.1371/journal.pone.0007935.s002 (3.39 MB TIF)
Figure S2 Left panel: Western blot analysis of SGLT1 proteins
in jejunum mucosa extracts from AMPKa22/2 and WT mice.
Densitometric analysis of the blots was performed using NIH
Image software and data are expressed as described above. Right
panel: Effect of luminal leptin on SGLT1 transport activity in
jejunum fragments from AMPKa22/2 and WT mice mounted in
Ussing chamber. Vehicle or leptin was added in the mucosal bath
2 minutes before challenge with 10 mM glucose. Electrogenic
chloride secretion in response to carbachol (100 mM) was used as a
control. Values for Isc are expressed as mean6SEM of net
increase in Isc (DIsc) in mA/cm2; n=5 mice in each group.
*P,0.05 and **P,0.01 vs. control.
Found at: doi:10.1371/journal.pone.0007935.s003 (3.77 MB TIF)
Figure S3 Summary of the mechanisms involved in the luminal
leptin regulation of GLUT5 and GLUT2 transporters. Luminal
leptin operating through leptin receptors phosphorylates/activates
ERK, AMPKa, and PKCbII leading to recruitment of more
GLUT2/GLUT5 into the BBM and the subsequent increase in
galactose and fructose transport across the jejunum into the blood.
Thereafter, leptin replenishes the cytoplasmic pool of these
transporters by increasing GLUT2 and GLUT5 mRNA levels.
Found at: doi:10.1371/journal.pone.0007935.s004 (6.90 MB TIF)
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